Martino E, Mele G, Vigna E, Morabito F, Gentile M
Mediterr J Hematol Infect Dis. 2025; 17(1):e2025006.
PMID: 39830800
PMC: 11740893.
DOI: 10.4084/MJHID.2025.006.
Testa U, Leone G
Mediterr J Hematol Infect Dis. 2025; 17(1):e2025005.
PMID: 39830797
PMC: 11740910.
DOI: 10.4084/MJHID.2025.005.
Merz M, Albici A, von Tresckow B, Rathje K, Fenk R, Holderried T
Hemasphere. 2025; 9(1):e70070.
PMID: 39822585
PMC: 11735948.
DOI: 10.1002/hem3.70070.
Gregorova J, Vlachova M, Vychytilova-Faltejskova P, Dostalova A, Ruzickova T, Vecera M
Hematol Oncol. 2025; 43(1):e70036.
PMID: 39804194
PMC: 11727818.
DOI: 10.1002/hon.70036.
Bernardi C, Beauverd Y, Tran T, Maulini M, Mappoura M, Morin S
Front Immunol. 2024; 15:1495233.
PMID: 39676854
PMC: 11638231.
DOI: 10.3389/fimmu.2024.1495233.
Transplant in myeloma: who, when, and why?.
Perrot A
Hematology Am Soc Hematol Educ Program. 2024; 2024(1):561-568.
PMID: 39643987
PMC: 11665519.
DOI: 10.1182/hematology.2024000580.
Survival Outcomes of Patients with Primary Plasma Cell Leukemia in the Era of Proteasome Inhibitors and Immunomodulatory Agents: A Real-Life Multicenter Analysis.
Atas U, Salim O, Iltar U, Yucel O, Kucukdiler Eroglu A, Aslan V
Turk J Haematol. 2024; 41(4):225-235.
PMID: 39501735
PMC: 11628765.
DOI: 10.4274/tjh.galenos.2024.2023.0450.
[Analysis of the prognostic factors in primary plasma cell leukemia in the era of novel agents].
Deng J, Jin X, Zhang Z, Zhou H, Yang G, Geng C
Zhonghua Xue Ye Xue Za Zhi. 2024; 45(7):645-650.
PMID: 39231768
PMC: 11388131.
DOI: 10.3760/cma.j.cn121090-20240129-00042.
Poor outcome despite modern treatments: A retrospective study of 99 patients with primary and secondary plasma cell leukemia.
Tessier C, LeBlanc R, Roy J, Trudel S, Cote J, Lalancette M
Cancer Med. 2024; 13(17):e70192.
PMID: 39225552
PMC: 11369989.
DOI: 10.1002/cam4.70192.
Atypical Plasma Cell Leukemia Mistaken for Acute Leukemia: A Case Report.
Seili-Bekafigo I, Torlakovic E, Grenko Malnar T, Damic M, Prka Z, Matusan Ilijas K
Medicina (Kaunas). 2024; 60(8).
PMID: 39202633
PMC: 11356772.
DOI: 10.3390/medicina60081351.
Venetoclax in the treatment of secondary plasma cell leukemia with translocation t(11;14): a case report and literature review.
Elsabah H, Ghasoub R, El Omri H, Benkhadra M, Cherif H, Y Taha R
Front Oncol. 2024; 14:1390747.
PMID: 39050574
PMC: 11266074.
DOI: 10.3389/fonc.2024.1390747.
Clinical features associated with poor response and early relapse following BCMA-directed therapies in multiple myeloma.
Rees M, Mammadzadeh A, Bolarinwa A, Elhaj M, Bohra A, Bansal R
Blood Cancer J. 2024; 14(1):122.
PMID: 39043638
PMC: 11266661.
DOI: 10.1038/s41408-024-01081-z.
Improved Outcome of Primary Plasma Cell Leukemia in the Current Era with the Use of Novel Agents and Autologous Bone Marrow Transplants-A Single Centre Experience.
Gupta D, Moule P, Aggarwal C, Kotwal J, Langer S, Saraf A
Indian J Hematol Blood Transfus. 2024; 40(3):400-406.
PMID: 39011239
PMC: 11246386.
DOI: 10.1007/s12288-023-01731-5.
R2-ISS staging combined with circulating plasma cells improves risk stratification for newly diagnosed multiple myeloma: a single-center real-world study.
Chu B, Wang Y, Gao S, Shi L, Lu M, Fang L
Ann Hematol. 2024; 103(9):3677-3690.
PMID: 38955826
PMC: 11358218.
DOI: 10.1007/s00277-024-05806-9.
[Chinese expert consensus on the application of flow cytometry for the detectin of circulating plasma cells in plasma cell disorders (2024)].
Zhonghua Xue Ye Xue Za Zhi. 2024; 45(4):313-321.
PMID: 38951057
PMC: 11167996.
DOI: 10.3760/cma.j.cn121090-20240117-00026.
Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management.
Rajkumar S
Am J Hematol. 2024; 99(9):1802-1824.
PMID: 38943315
PMC: 11404783.
DOI: 10.1002/ajh.27422.
Multiple myeloma.
Malard F, Neri P, Bahlis N, Terpos E, Moukalled N, Hungria V
Nat Rev Dis Primers. 2024; 10(1):45.
PMID: 38937492
DOI: 10.1038/s41572-024-00529-7.
A Clinical Perspective on Plasma Cell Leukemia: A Single-Center Experience.
Li A, Kamangar F, Holtzman N, Rapoport A, Kocoglu M, Atanackovic D
Cancers (Basel). 2024; 16(11).
PMID: 38893268
PMC: 11172213.
DOI: 10.3390/cancers16112149.
Bone marrow stromal cells induce chromatin remodeling in multiple myeloma cells leading to transcriptional changes.
Binder M, Szalat R, Talluri S, Fulciniti M, Avet-Loiseau H, Parmigiani G
Nat Commun. 2024; 15(1):4139.
PMID: 38755155
PMC: 11098817.
DOI: 10.1038/s41467-024-47793-5.
Prognostic Implications of Circulating Plasma Cell Percentage in Multiple Myeloma and Primary Plasma Cell Leukemia Defined by New Criteria.
Jin X, Jiang X, Li H, Shen K, Liu S, Chen M
Acta Haematol. 2024; 148(1):48-57.
PMID: 38626745
PMC: 11809457.
DOI: 10.1159/000538658.